Protocol Ledger

NCT05168566 · Phase II · RECRUITING

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT05168566 sponsored by Teligene US in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-01 Enrollment: 128 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05168566
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)128 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05168566
Protocol FieldVerified Registry Value
NCT IdentifierNCT05168566
Consolidated Lead SponsorTeligene US
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment128 participants (ESTIMATED)
Registered Start Date2022-09-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05168566
Hospital Research SiteLocationSite Profile
University of Maryland Medical CenterBaltimore, MDOpen Hospital Dossier ->
MD Anderson Cancer CenterHouston, TXOpen Hospital Dossier ->
Virginia Cancer SpecialistsFairfax, VAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI